RCUS
Price
$10.39
Change
+$0.48 (+4.84%)
Updated
Aug 15 closing price
Capitalization
1.11B
86 days until earnings call
SYRE
Price
$16.95
Change
+$0.09 (+0.53%)
Updated
Aug 15 closing price
Capitalization
1.02B
80 days until earnings call
Interact to see
Advertisement

RCUS vs SYRE

Header iconRCUS vs SYRE Comparison
Open Charts RCUS vs SYREBanner chart's image
Arcus Biosciences
Price$10.39
Change+$0.48 (+4.84%)
Volume$883.98K
Capitalization1.11B
Spyre Therapeutics
Price$16.95
Change+$0.09 (+0.53%)
Volume$536.98K
Capitalization1.02B
RCUS vs SYRE Comparison Chart in %
Loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCUS vs. SYRE commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (RCUS: $10.39 vs. SYRE: $16.95)
Brand notoriety: RCUS and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 95% vs. SYRE: 90%
Market capitalization -- RCUS: $1.11B vs. SYRE: $1.02B
RCUS [@Biotechnology] is valued at $1.11B. SYRE’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, RCUS is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 7 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • RCUS’s TA Score: 7 bullish, 2 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than SYRE.

Price Growth

RCUS (@Biotechnology) experienced а +14.68% price change this week, while SYRE (@Biotechnology) price change was +11.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

RCUS is expected to report earnings on Nov 11, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.11B) has a higher market cap than SYRE($1.02B). SYRE YTD gains are higher at: -27.191 vs. RCUS (-30.222). SYRE has higher annual earnings (EBITDA): -214.36M vs. RCUS (-377M). RCUS has more cash in the bank: 997M vs. SYRE (565M). SYRE has less debt than RCUS: SYRE (0) vs RCUS (60M). RCUS has higher revenues than SYRE: RCUS (141M) vs SYRE (0).
RCUSSYRERCUS / SYRE
Capitalization1.11B1.02B108%
EBITDA-377M-214.36M176%
Gain YTD-30.222-27.191111%
P/E RatioN/A1.68-
Revenue141M0-
Total Cash997M565M176%
Total Debt60M0-
FUNDAMENTALS RATINGS
RCUS vs SYRE: Fundamental Ratings
RCUS
SYRE
OUTLOOK RATING
1..100
7610
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
5859
P/E GROWTH RATING
1..100
9884
SEASONALITY SCORE
1..100
5016

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (49) in the Pharmaceuticals Major industry is in the same range as SYRE (73). This means that RCUS’s stock grew similarly to SYRE’s over the last 12 months.

RCUS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that RCUS’s stock grew similarly to SYRE’s over the last 12 months.

RCUS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as SYRE (99). This means that RCUS’s stock grew similarly to SYRE’s over the last 12 months.

RCUS's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as SYRE (59). This means that RCUS’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (84) in the Pharmaceuticals Major industry is in the same range as RCUS (98). This means that SYRE’s stock grew similarly to RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
82%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCOTX19.18N/A
N/A
Victory Pioneer Core Equity C
FDLSX20.98-0.01
-0.05%
Fidelity Select Leisure
PMIVX11.03-0.01
-0.09%
Putnam Multi-Asset Income R6
MXVIX41.46-0.12
-0.29%
Empower S&P 500® Index Investor
LZSCX11.12-0.44
-3.81%
Lazard US Small Cap Equity Select Instl

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+4.84%
XNCR - RCUS
52%
Loosely correlated
+0.39%
IDYA - RCUS
49%
Loosely correlated
-0.16%
CRNX - RCUS
48%
Loosely correlated
+3.47%
SYRE - RCUS
48%
Loosely correlated
+0.53%
ACLX - RCUS
47%
Loosely correlated
+3.09%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.53%
IDYA - SYRE
61%
Loosely correlated
-0.16%
CGON - SYRE
60%
Loosely correlated
-1.00%
BEAM - SYRE
59%
Loosely correlated
+1.08%
XNCR - SYRE
57%
Loosely correlated
+0.39%
CRNX - SYRE
55%
Loosely correlated
+3.47%
More